Interleukin 2 as a potential cancer marker in patients after kidney transplantation

Agnieszka Witkowska 1, Joanna Zywiec 1, Agnieszka Strozik 1, Sylwia Gorczynska-Kosiorz 1, Wanda Trautsolt 1, Barbara Strzalka-Mrozik 2, Magdalena Kimsa 2, Aleksander Owczarek 3, Beata Stępień 4, Urszula Mazurek 5, Władysław Grzeszczak 6, Janusz Gumprecht 6
1 - Department of Internal Medicine, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland
2 - Department of Molecular Biology, Medical University of Silesia, Sosnowiec, Poland
3 - Division of Statistics, Medical University of Silesia, Sosnowiec, Poland
4 - Internal Practice, Bytom, Poland
5 - Department of Molecular Biology, Medical University of Silesia, Sosnowiec, Poland
6 - Department of Internal Medicine, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland
Ann Agric Environ Med
2015; 22 (2):
ICID: 1152087
Article type: Original article
 
 
Introduction. Transplant recipients have a significantly greater incidence of cancer, compared with the general population, who are referred to immunosuppressive therapy as an additional malignancy risk factor. Therefore, there is a need to search for an easy in clinical practice neoplasm predictor, especially for this group of patients.
Materials and methods. A group of 74 (43M and 31F; aged 46.8 ± 12 years) kidney transplant recipients was investigated in a three-year follow-up study. During the time of observation, 7 patients were diagnosed with neoplasm (7.4 ± 1.5 years after transplantation). A serum level of IL2 (ELISA test) and mRNA level of IL1beta, IL10 and TNFalfa in peripheral mononuclear blood cells – PBMCs (QRT – PCR method) were measured in every year of observation. Analysis of variances and t-Student test were used in groups mean comparison:
N – patients developing malignant neoplasm group (24 probes);
M – set of probes from patients with malignancies at the moment of diagnosis (11 probes);
P – set of probes from patients before developing malignant neoplasm (10 probes);
C – control group of healthy transplant recipients (31 probes).
Results. Among the analyzed agents, only serum IL2 level differed between the analyzed groups, with higher values in the M compared with the P group (p<0.05) and with C group (p<0.01). There were no differences neither between N and C or P and C groups (p = 0.98), nor any correlation between IL2 and IL1b, IL2 and TNFalfa.
Conclusions. The results may indicate that IL2 serum level might be consider as a useful late unspecific cancer marker, although larger studies should yield verification of this finding.

DOI: 10.5604/12321966.1152087
PMID 26094531 - click here to show this article in PubMed
  FULL TEXT STATS

Recommend this article to:

Name:
E-mail:
From:
Language:


Related articles in IndexCopernicus™
     Kidney Transplantation [815 related records]
     interleukin 2 [2 related records]
     cancer marker [0 related records]



 

Related articles

A Kujawa-Szewieczek, M Adamczak,
Analysis of Clostridium difficile infections in pa...
Background: Few studies have evaluated the incidence and risk factors of Clostridium difficile infection (CDI) in the adult Polish population, in particular in solid organ recipients hospitalized at the nephrological ward. Aim: The aim of this study...
ABSTRACT
I BAGDASAROVA, S FOMINA,
CHRONIC KIDNEY DISEASE IN CHILDREN AND RENAL REPLA...
Classification of Chronic Kidney Disease and stages of Chronic Renal Failure in children were compared. There was presented adapted Schwartz formula for estimated Glomerular Filtration Rate. Prevalence of the genitourinary system diseases in Ukrainia...
ABSTRACT
I Mikolašević, S Milić,
Kronična hepatitis C virusna infekcija kod pacije...
Cilj našeg istraživanja bio je utvrditi utjecaj kronične HCV infekcije na preživljenje pacijenata s bubrežnim transplantatom kao i preživljenje samog bubrežnog transplantata. Ispitanici i metode: Retrospektivnom analizom analizirali smo 492 pa...
ABSTRACT